Win Min HanRimke BijkerEzhilarasi ChandrasekaranSanjay PujariOon Tek NgPenh Sun LyMan Po LeeKinh Van NguyenYu Jiun ChanCuong Duy DoJun Yong ChoiRomanee ChaiwarithTuti Parwati MeratiSasisopin KiertiburanakulIskandar AzwaSuwimon KhusuwanFujie ZhangYasmin Mohamed GaniJunko TanumaShashikala SangleRossana DitangcoEvy YunihastutiJeremy RossAnchalee AvihingsanonHospital Sungai BulohBeijing Ditan Hospital Capital Medical UniversityVHS Medical Centre IndiaGokilaBach Mai HospitalUniversitas UdayanaUniversity of Indonesia, RSUPN Dr. Cipto MangunkusumoChulalongkorn UniversityKirby InstituteNational Center for Global Health and MedicineThe HIV Netherlands Australia Thailand Research CollaborationYonsei University College of MedicineFaculty of Medicine, Ramathibodi Hospital, Mahidol UniversityQueen Elizabeth Hospital Hong KongUniversity of Malaya Medical CentreVeterans General Hospital-TaipeiTan Tock Seng HospitalBJ Government Medical College and Sassoon General HospitalsNational Hospital for Tropical DiseasesamfAR - The Foundation for AIDS ResearchResearch Institute for Health SciencesInstitute of Infectious DiseasesChiangrai Prachanukroh HospitalNational Center for HIV/AIDS2020-11-182020-11-182020-12-01Journal of acquired immune deficiency syndromes (1999). Vol.85, No.4 (2020), 489-497194478842-s2.0-85095399729https://repository.li.mahidol.ac.th/handle/20.500.14594/60025BACKGROUND: We validated the Data collection on Adverse events of anti-HIV Drugs (D:A:D) full-risk and short-risk score models for chronic kidney disease (CKD) in the Asian HIV cohorts. SETTINGS: A validation study among people living with HIV (PLHIV) aged ≥18 years among the cohorts in the Asia-Pacific region. METHODS: PLHIV with a baseline estimated glomerular filtration rate > 60 mL/min/1.73 m were included for validation of the D:A:D CKD full version and short version without cardiovascular risk factors. Those with <3 estimated glomerular filtration rate measurements from baseline or previous exposure to potentially nephrotoxic antiretrovirals were excluded. Kaplan-Meier methods were used to estimate the probability of CKD development. The area under the receiver operating characteristics was also used to validate the risk score. RESULTS: We included 5701 participants in full model {median 8.1 [interquartile range (IQR) 4.8-10.9] years follow-up} and 9791 in short model validation [median 4.9 (IQR 2.5-7.3) years follow-up]. The crude incidence rate of CKD was 8.1 [95% confidence interval (CI): 7.3 to 8.9] per 1000 person-years in the full model cohort and 10.5 (95% CI: 9.6 to 11.4) per 1000 person-years in the short model cohort. The progression rates for CKD at 10 years in the full model cohort were 2.7%, 8.9%, and 26.1% for low-risk, medium-risk, and high-risk groups, and 3.5%, 11.7%, and 32.4% in the short model cohort. The area under the receiver operating characteristics for the full-risk and short-risk score was 0.81 (95% CI: 0.79 to 0.83) and 0.83 (95% CI: 0.81 to 0.85), respectively. CONCLUSION: The D:A:D CKD full-risk and short-risk score performed well in predicting CKD events among Asian PLHIV. These risk prediction models may be useful to assist clinicians in identifying individuals at high risk of developing CKD.Mahidol UniversityMedicineArticleSCOPUS10.1097/QAI.0000000000002464